Blog

Joanna Shields speaks at the Global Partnership on Artificial Intelligence

At the Global Partnership on Artificial Intelligence (GPAI) summit, Benevolent AI CEO Joanna Shields shared her belief that humanity should be at the heart of AI.

Last week international AI experts across industry, civil society, academia and government from over 60 countries came together virtually for the first plenary of the Global Partnership on Artificial Intelligence (GPAI) in Montreal. At the end of an immensely challenging year, the members reflected on the power AI has to fuel discoveries, empower scientists and shape the world when used responsibly.

Our CEO Joanna Shields, proudly represented the United Kingdom as the newly elected Chair of the Steering Committee and the Multistakeholder Group. She shared the stage with Prime Minister Justin Trudeau and the President of France, Emmanuel Macron, who co-led the effort to establish GPAI through their 2018 and 2019 G7 presidencies. The two world leaders addressed the summit with their vision to guide the responsible development and use of AI globally, with Trudeau describing how ‘we must not forget that positive change doesn’t happen by itself, we have to choose it’.

Joanna opened the final plenary of the day with a speech that echoed these words. She focused on the power human ingenuity and AI has to propel us forward, and ultimately benefit all. She described how AI is at its most powerful when it is the result of a fusion between humanity and technology, as well as the need for purposeful technology which reflects the values of our society.

She drew on her learnings from the first digital revolution and the necessity to ensure that frameworks and standards are embedded in our development of new AI. The purpose of GPAI is to provide these guiding principles because, in her words, ‘AI is a powerful force that we cannot afford to underestimate’.


More Posts

You Might Also Like

News
Data from Eli Lilly’s COV-BARRIER trial shows baricitinib reduced deaths in hospitalised COVID-19 patients by 38%
The latest data published in Eli Lilly’s Phase 3 randomised, double-blind, placebo-controlled study (COV-BARRIER) shows the largest clinical effect reported to date for a reduction in mortality in the COVID-19 patient population
Apr 8, 2021
News
BenevolentAI named as one of Fierce Medtech’s Fierce 15 of 2020
BenevolentAI was selected as one of the most promising private companies in the industry by Fierce Medtech in its Fierce 15 2020 list.
Mar 8, 2021
Blog
Tech Nation Visa: the gateway to world-leading UK tech jobs
Drawing attention to the Tech Nation Visa, a great initiative that enables the brightest international talent to live and work in the UK.
Feb 19, 2021
News
BenevolentAI announces first patient dosed in its Atopic Dermatitis clinical trial
A molecule designed and developed by BenevolentAI to treat mild to moderate Atopic Dermatitis has entered clinical trials.
Feb 11, 2021
News
BenevolentAI and AstraZeneca achieve collaboration milestone with novel AI-generated chronic kidney disease target
BenevolentAI and AstraZeneca hit collaboration milestone with an AI-generated CKD target from the partnership entering AstraZeneca’s portfolio.
Jan 27, 2021
News
ACTT-2 trial results published in the New England Journal of Medicine validate baricitinib’s efficacy in combination with remdesivir in hospitalised COVID-19 patients
Peer-reviewed data from the ACTT-2 further validate BenevolentAI’s hypothesis for baricitinib as a potential COVID-19 treatment.
Jan 15, 2021